Company Overview

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for chronic renal and inflammatory diseases with high unmet medical need. The company operates within the biotechnology and pharmaceutical research industry, with a strategic emphasis on kidney diseases and conditions driven by dysregulated inflammation, particularly the inflammasome pathway.

ZyVersa’s core strategy centers on advancing novel therapeutic candidates targeting biological mechanisms implicated in chronic kidney disease (CKD) and rare renal disorders. The company was founded in 2014 and is headquartered in the United States. Over time, ZyVersa has evolved from a research-focused entity into a publicly traded clinical-stage company, listed on Nasdaq under the ticker ZVSA, with its development programs supported by licensed intellectual property and preclinical-to-clinical translational research.

Business Operations

ZyVersa does not have commercialized products and does not generate product revenue; its operations are focused on drug discovery, preclinical development, and early-stage clinical development. The company’s primary business activities are organized around two therapeutic platforms: VAR 200, a cholesterol efflux mediator targeting renal lipid accumulation, and IC 100, a monoclonal antibody targeting ASC, a central adaptor protein in inflammasome signaling.

Operational activities are conducted primarily in the United States through a combination of internal management and outsourced research organizations, including contract research organizations (CROs) and manufacturing partners. ZyVersa controls its development assets through exclusive licenses to underlying patents and relies on external collaborators for clinical trial execution, regulatory support, and manufacturing of investigational drug products.

Strategic Position & Investments

ZyVersa’s strategic direction is focused on advancing differentiated therapies that address disease mechanisms not adequately targeted by existing treatments. The company’s growth initiatives prioritize the clinical advancement of VAR 200 for indications such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases, as well as IC 100 for inflammatory and neurological conditions where inflammasome activation is implicated.

Rather than pursuing large-scale acquisitions, ZyVersa’s investment strategy has emphasized in-licensing and internal development of novel assets. The company has not reported ownership of revenue-generating subsidiaries or a diversified investment portfolio. Its value proposition is centered on its intellectual property estate, early clinical data, and the potential applicability of its inflammasome-targeting technology across multiple inflammatory disease indications.

Geographic Footprint

ZyVersa Therapeutics is headquartered in the United States, with corporate operations based in Florida. The company’s research, development, and administrative activities are primarily U.S.-based, while aspects of preclinical testing, manufacturing, and clinical trial support may involve international vendors and research partners.

Although ZyVersa does not maintain physical offices outside the United States, its development programs are designed for global applicability, and future clinical trials and commercialization efforts are expected to target major pharmaceutical markets in North America, Europe, and potentially Asia, subject to regulatory approvals and capital availability.

Leadership & Governance

ZyVersa is led by an executive team with experience in biotechnology, drug development, and corporate strategy, overseen by a board of directors responsible for governance, capital allocation, and long-term strategic oversight. The leadership emphasizes disciplined capital management, scientific differentiation, and advancing assets through value-inflecting clinical milestones.

Key executives include:

• Stephen C. Glover – Chief Executive Officer
• Brian J. Lian – Chief Financial Officer
• Douglas K. Swirsky – Chief Operating Officer
• Paul J. Coppola – Chief Scientific Officer

The leadership team’s stated strategic vision focuses on translating novel science into clinically meaningful therapies while leveraging partnerships and external expertise to advance development efficiently.